- Company
- 8 multinational companies name new CEOs in Korea
- by Eo, Yun-Ho Dec 3, 2019 03:21pm
- Sources report eight global pharmaceutical companies have appointed new CEOs of Korean affiliates this year only. Daily Pharm surveyed a roster of major 30 multinational companies’ Korean affiliate CEOs as of Dec. 4, and found about 28 percent of the companies have either replaced or newly appointed the top executive personnel. Whi
- Company
- Counterattack of Valsartan’s Pharmaceuticals
- by Chon, Seung-Hyun Dec 3, 2019 05:54am
- Pharmaceuticals filed an alleged class action lawsuit against health authorities. A lawsuit was filed preemptively that the government can not accept the Valsartan claim. Cost liability for follow-up of impurity drugs has been determined in court. According to the industry, 36 pharmaceutical companies recently filed a lawsuit to confirm th
- Company
- ECCK “Revised Pricing Negotiation Guideline Violates FTA"
- by Kim, Jin-Gu Dec 3, 2019 05:53am
- Europe-based global pharmaceutical companies with offshoots in Korea have filed official complaints on ‘additional requirements under side agreement’ added to drug pricing negotiation procedure in Korea. They claim the new changes could violate the principles of Korea-EU Free Trade Agreement (FTA). European Chamber of Commerce in Ko
- Company
- Drug Committees pass oral Fabry treatment Galafold
- by Eo, Yun-Ho Dec 2, 2019 05:57am
- The world’s first orally taken Fabry disease treatment ‘Galafold’ is landing its code on tertiary hospital drug list. According to pharmaceutical industry, Handok’s Galafold (migalastat) has been passed by drug committees (DC) in specialized healthcare institutes for rare disease care, like Seoul Asan Medical Center, Ajou University
- Company
- The Answer is in RSA expansion and undisclosed pricing
- by Kim, Jung-Ju Nov 29, 2019 10:54pm
- Maybe the answer has been before our very eyes all along. If Korea Passing occurs when other foreign countries start referring to Korean drug pricing, then it could be avoided by preventing them from referencing. Otherwise, drug could be price at a moderate level to avoid Korea Passing regardless of other countries. Theoretically t
- Company
- PPC signs MOU with Clinerion to shorten clinical period
- by Eo, Yun-Ho Nov 29, 2019 06:32am
- Asia-specific CRO PPC (Protech Pharmaservices Corporation) recently signed an MOU with Clinerion, Switzerland, to shorten the time for clinical institution selection and patient registration. Through this partnership, PPC expects to use Clinerion's Patient Network Explorer platform to accelerate enrollment of subjects in global clinical tr
- Company
- Lynparza tablet requests for expanded reimbursement
- by Eo, Yun-Ho Nov 29, 2019 06:31am
- Anticancer treatment Lynparza is applying for insurance reimbursement on its orally taken tablet formulation. Pharmaceutical industry source tells AstraZeneca Korea has recently submitted reimbursement application for extended indication of a poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib). The anticancer treatment is now
- Company
- GLP-1 diabetes, Trulicity runs at a high speed
- by An, Kyung-Jin Nov 28, 2019 10:45am
- Once-weekly diabetes treatment, Trulicity, overwhelms the GLP-1 analog market. The company's annual sales are over &8361;30 billion, exceeding &8361;27 billion in nine months. The market grew to more than 98% with a single item, increasing the overall market size. According to the drug market research agency IQVIA on the 28th, Trulicit
- Company
- BMS-Celgene Korea promotes Kim Jinyoung as new CEO
- by Eo, Yun-Ho Nov 28, 2019 10:19am
- The decision has been made and it was a promotion from within. Kim Jinyoung (43), a former acting CEO, was appointed as the CEO of merged BMS-Celgene Korea. Kim used to serve as a Head of Legal and Compliance in BMS Korea, but was appointed as an acting CEO after former President Park Hye-sun (49) left the office. Kim had been active as
- Company
- Ildong great likelihood to sell strongly 'Otrivin' by GSK
- by Jung, Hye-Jin Nov 28, 2019 06:14am
- Ildong pharmaceuticals has the most potential of otc vendor for 10 GSK items. It is possible that A distributor, Zuellig Pharma Korea will be charge of selling Lamisil. According to the industry on the 26th, GSK, Ildong Pharmaceuticals and Zuellig Pharma Korea are in the last negotiations over the right to sell 10 generic drugs. A
